CLINICAL TRIALS – 2021

SL. No Topic Name Name of faculty Name of Funding Agency
1. Protocol Number: AC-065B302
Protocol Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical and/or interventional treatment Chronic Thromboembolic Pulmonary Hypertension(NEW ) 		Dr. Prasad M.R. JANSSEN
2. A   Randomized double blind, placebo controlled, multicenter Trial, assessing the impact of mechanism on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION- 2 PREVENT)          (NEW ) Dr. Prasad M.R NOVARTIS
3. Title “ ZEUS -Effects of zilltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation. (new) Dr. Prasad M.R.

 

CLINICAL TRIALS – 2020

Sl. No Topic Name Name of faculty Name of Funding Agency
1 Protocol No-RLS/PMS/2018/01
Protocol title-prospective, multi-center, phase IV study to evaluate safety and efficacy of tenecteRelTM (tenecteplase manufacture by Reliance Life Sciences Pvt ltd) Protocol No: RLS/PMS/2017/01; Version 2.0, Dated: 24 Jun 2019(ON GOING )		 Dr.Sameer Amber Relaince India PVt Ltd
2 Protocol No-TQJ230A12301
Protocol title- A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular event in patients with established cardiovascular disease  (HORIZON ) Lp(a)(ON GOING )		 Dr. Prasad MR Novartis
 

3.

 YOGA CARE TRIAL completed  (ICMR) Dr. Prasad M.R. ICMR

 

CLINICAL TRIALS – 2019

Sl. No Topic Name Name of faculty Name of Funding Agency
1 Protocol No and Title:  My Val-1: A prospective, Multicentre, single arm, open label study of My ValTM transacattheter Aortic Valve replacement system in the treatment of severe symptomatic native aortic valve stenosis completed   Dr.Suresh Patted Meril life
2 Protocol No: CTQJ230A12001
Protocol Title : Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotéine(a) levels among patients with established cardiovascular diseaseCTOJ(ON GOING ) 		Dr.Prasad MR Novartis

 

CLINICAL TRIALS  2018

SL. No Topic Name Name of faculty Name of Funding Agency
1 Protocol title: BioMime™Morph- KLES: A retrospective, observational, real-world, safety and performance evaluation of BioMime™Morph Sirolimus Eluting Coronary Stent System for coronary artery lesions (completed ) Dr.Suresh Patted Meril life
2 Study Number/Name: EFC14875 / the SCORED Trial
Study Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function (completed) 		Dr.Prasad MR Sanofil Aventis
3. Protocol Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk.
STUDY NUMBER/NAME: EFC14828/Amplitude-O   (completed  )		 Dr. Prasad MR Sanofil Aventis

 

CLINICAL TRIALS  2016

Sl. No Topic Name Name of faculty Name of Funding Agency
1 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome’’

( Completed )

 Dr.Sanjay Porwal Sunpharma
2 Protocol: A prospective, Single-centre, Observational, real world, Post-marketing surveillance to evaluate safety and performance of the BioMimeTM Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions.

(completed)

 Dr.Suresh Patted Meril life